



BAL PHARMA LIMITED

CIN # L85110KA1987PLC008368

Head Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099, url : www.balpharma.com

AUDITED FINANCIAL RESULTS FOR THE IV th QUARTER & YEAR ENDED 31.03.2014

(Rs.in Lakhs)

Sr. No:	Particulars	Quarter Ended			Year ended	
		31.03.2014 Audited	31.12.2013 Unaudited	31.03.2013 Audited	31.03.2014 Audited	31.03.2013 Audited
1	Net Sales/Income from operations (Net of Excise Duty)	4,662.07	4,327.62	4,155.63	17,341.40	14,430.36
	Other Operating Income	245.14	97.51	126.24	545.80	361.08
	Net Income from Sales/Services	4,907.21	4,425.13	4,281.87	17,887.20	14,791.44
2	Expenditure					
	a) Increase/decrease in stock in trade and WIP	107.07	(13.28)	100.48	95.94	244.71
	b) Consumption of Raw Materials/ Packing Material	2,435.20	2,219.71	2,118.81	8,911.84	7,134.07
	c) Purchase of Stock in Trade	144.04	144.79	121.64	515.41	440.16
	d) Employee Cost	744.86	714.15	588.24	2,812.36	2,364.93
	e) Depreciation and amortisation expenses	101.72	110.63	183.66	473.97	481.22
	f) Other Expenditure	1,035.27	905.49	775.82	3,763.97	2,885.70
	g) Total	4,568.16	4,081.49	3,888.64	16,573.49	13,550.78
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	339.05	343.64	393.23	1,313.71	1,240.66
4	Other Non-operating Income	37.20	4.61	36.19	64.63	65.93
5	Profit before Interest and Exceptional items (3+4)	376.25	348.25	429.42	1,378.34	1,306.59
6	Finance Costs	181.85	177.36	200.55	715.74	797.68
7	Profit after Interest but before Exceptional items	194.40	170.89	228.87	662.60	508.91
8	Exceptional items	-	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	194.40	170.89	228.87	662.60	508.91
10	Tax expenses	58.63	31.85	16.68	155.37	80.56
11	Net Profit /Loss from ordinary Activities after Tax	135.77	139.04	212.19	507.23	428.35
12	Extra ordinary items	-	-	-	-	-
13	Net Profit / Loss for the period	135.77	139.04	212.19	507.21	428.35
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,111.14	1,057.36	1,057.36	1,111.14	1,057.36
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				3,283.79	2,948.22
16	EPS (in Rs.)					
	a) Basic	1.25	1.32	2.01	4.77	4.05
	b) Diluted	1.21	1.32	2.01	4.60	4.05
17	Public shareholding					
	- Number of Shares	5,142,086	5,142,086	5,142,086	5,142,086	5,142,086
	- Percentage of shareholding	46.28	48.63	48.63	46.28	48.63
18	Promoters & Promoter group Shareholding					
	a) Pledged / Encumbered					
	- Number of Shares	-	-	-	-	-
	- Percentage of shareholding	-	-	-	-	-
	b) Non-encumbered					
	- Number of Shares	5,969,302	5,431,538	5,431,538	5,969,302	5,431,538
	- Percentage of shareholding	53.72	51.37	51.37	53.72	51.37

Notes:

1 Statement of assets and liabilities as on 31.03.2014 is as follows

Particulars	(Rs Lakhs)	
	31.03.2014	31.03.2013
Share Capital	1,111.14	1,057.36
Resurves & Surplus	3,720.18	3,283.79
Money received against share warrant	173.64	120.68
	5,004.96	4,461.83
Non Current Liabilities		
Long-term borrowings	797.01	167.10
Deferred tax liabilities (Net)	823.72	823.72
Other long term liabilities	65.59	181.00
Long-term provisions	105.98	83.50
	1,792.30	1,255.32
Current liabilities		
Short- term borrowings	4,274.99	4,435.97
Trade payables	3,353.09	3,205.64
Other current liabilities	865.93	1,496.93
Short- term provisions	183.14	128.07
	8,677.15	9,266.61
TOTAL	15,474.41	14,983.76
Non- current assets		
Fixed Assets	5,542.47	5,270.31
Non- current investments	1.50	1.50
Long term loans and advances	396.43	383.46
Other non-current assets	22.36	26.59
	5,962.76	5,681.86
Current assets		
Inventories	3,171.42	3,368.70
Trade receivables	4,548.82	4,343.90
Cash and cash equivalents	302.42	453.35
Short-term loans and advances	1,476.20	1,110.71
Other current assets	12.80	25.23
	9,511.65	9,301.90
TOTAL	15,474.41	14,983.76

2 The above audited financials results as reviewed by the Audit Committee were approved by the Board of Directors at its meeting held on 28.05.2014

3 The Board has recommended a dividend of Re 1/- per Equity Share of Rs 10 each, i.e. 10%, for the financial year 2013-14

4 The financial results for the quarter ended 31.03.2013 and 31.03.2014 are balancing figures between the audited figures in respect of full financials year and the published figures up to third quarter.

5 The Company has successfully concluded the preferential allotment of 22,98,748 Equity Shares at Rs 21/- per Equity Share to the Promoters and strategic investors and the proceeds of the issue are deployed for CAPEX and working capital requirements of the Company.

6 Investor grievances : Outstanding at the beginning of the quarter ; Nil, received during the quarter ; 48; resolved during the quarter 48; pending at the end of the quarter; Nil.

7 Previous year figures were regrouped/rearranged to conform to the classification of current year.

8 As the Company deals with single product i. e Pharmaceuticals, segment wise figures are not furnished.

Bangalore
28th May 2014

By order of the Board of Directors
For Bal Pharma limited

Shailesh Siroya
Managing Director